Advancing Health Equity With the Mount Sinai Million Health Discoveries Program
An essential part of achieving health equity is the fair collection of genomic data, ensuring that informed health care decisions can reflect the unique, diverse genomes of all cultures. Currently, there is a lack of diversity in genomic research data. This limits what we can uncover about health and potential treatments for our global population.
Expanding diversity among participants in genomic research can bridge these gaps, advancing our understanding of human genetics for all communities. One ambitious initiative that strives to diversify this data is the Mount Sinai Million Health Discoveries Program.
Mount Sinai Health System’s Health Equity Data Assessment (HEDA) team met with leaders of the program who expressed their challenge with identifying the ethnic identities of Mount Sinai patients participating in the program. HEDA was quickly able to assist in rectifying the data issue, which resulted in increasing the ethnic identities from 0.5 percent to 66 percent.
This assistance will have a significant impact on the program objectives. A hypothesis was formulated in the Measures and Outcomes section of the HEDA Hub. The HEDA team will track progress towards the program’s goal of reaching a million patients.
The Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai leads this project and aims to sequence the genomes of one million Mount Sinai patients over the next five years. It seeks to integrate health and research data to drive discoveries that directly benefit a diverse patient population.
Mount Sinai Million is poised to serve as a model for embedding genetics into routine clinical care. By leveraging data from one of the world’s most diverse patient populations within a massive New York City health system, this program seeks to deepen our understanding of the connections between genetics and disease.
In a recent conversation with Alexander Charney, MD, PhD, Director, The Charles Bronfman Institute for Personalized Medicine, and Associate Professor, Genetics and Genomic Sciences, Psychiatry, Neuroscience, Neurosurgery, and Artificial Intelligence and Human Health, Icahn Mount Sinai; and Lea K. Davis, PhD, Scientific Director of the Mount Sinai Million Health Discoveries Program, The Charles Bronfman Institute for Personalized Medicine, and Associate Professor of Medicine (Data-Driven and Digital Medicine), Icahn Mount Sinai, we gained further insight into this initiative.
Dr. Charney explains: “Our goal is to develop personalized treatments tailored not only to the disease but to the individual’s genetic makeup, which we know varies significantly across populations.”
“Equity is a core value of the scientific vision for the Mount Sinai Million,” says Dr. Davis. “We are thrilled to connect the program with HEDA and are looking forward to supporting equity-focused research through the development of this incredible resource.”
Reflecting on the broader impact, Dr. Charney says the initiative “isn’t just about collecting data; it’s about improving lives.” He envisions a health care system where genetic insights enable clinicians to make more informed, individualized decisions.
“With this kind of data,” he says, “we’re not just diagnosing based on symptoms—we’re diagnosing based on a person’s unique genetic and biological profile, which could mean a huge leap in effectiveness.”
With this forward-thinking approach, Dr. Charney and the Mount Sinai team are working toward a future where each person’s treatment is precise, effective, and, above all, personalized.
To enroll as a participant or to learn more about the Mount Sinai Million Health Discoveries Program, visit mountsinaimillion.org.